Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Core / Intermediate Bond · T. Rowe Price

MML Barings Diversified Bond Fund Class A (MDVAX)

Ticker MDVAX · · Holdings as of Jun 30, 2026

Expense ratio
1.09%$109/yr per $10k
5-yr return
−0.8%annualized
1-yr return
+3.8%as of Dec 2025
Net assets
$71.1Mall share classes
Holdings
359

Bottom line

Is MDVAX a good fund? The bottom line

MDVAX is the Class A share class of MML Barings Diversified Bond Fund, a managed core / intermediate bond mutual fund from T. Rowe Price.

It charges 1.09% — about $109 a year on every $10,000 invested, more expensive than 76% of core / intermediate bond funds we track.

It returned +3.8% over one year, −0.8% a year over five years, +2.0% a year over ten (as of Dec 31, 2025, per its prospectus).

With $71.1 million in net assets and 359 holdings, its largest position is State Street Global Advisors (2.4%) and the top 10 make up 11.7% of the portfolio.

This share class carries a front-end sales charge of up to 4.25%; a no-load class or ETF alternative can avoid it.

What stands out

  • Broadly diversified (359 holdings)

What to watch

  • Expensive for its category (1.09%)
  • 5-year return in the bottom quarter of its category
  • Front-end sales load up to 4.25%
  • 12b-1 marketing fee of 0.25% a year
  • High turnover (265% a year) can mean more taxable distributions

Updated Nov 19, 2026

What MDVAX invests in

This Fund seeks a superior total rate of return, with an emphasis on current income, by investing in fixed income instruments.

Principal Investment Strategies Under normal circumstances, the Fund invests at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in fixed income securities. These typically include: U.S. dollar-denominated corporate obligations and bank loans, securities issued or guaranteed by the U.S. Government or its agencies or instrumentalities, U.S. and foreign issuer dollar-denominated bonds including, but not limited to, corporate obligations, government and agency issues, private placement bonds, securities subject to resale pursuant to Rule 144A, convertible bonds, subordinated loans or debt, and mortgage-backed and other asset-backed securities, including collateralized bond and loan obligations. The Fund may invest up to 25% of its total assets in securities that are not denominated in ?U.S. dollars including, but not limited to, corporate…

From the fund's prospectus (filed Jan 30, 2026).

MDVAX performance

Average annual total returns
1 yr5 yr10 yr
MDVAX+3.8%−0.8%+2.0%
Core / Intermediate Bond median+7.2%+1.4%+3.0%

Source: Fund prospectus, as of Dec 31, 2025

Full MDVAX performance history →

What MDVAX costs

On a $10,000 investment, MDVAX's 1.09% expense ratio costs about $109 a year. The prospectus estimates $1,829 in total costs over 10 years (assuming 5% annual returns). The median core / intermediate bond fund charges 0.71%.

See the full MDVAX fee table →

MDVAX top 10 holdings

#Holding% of fund
1State Street Global Advisors2.40%
2New Residential Mortgage Loan Trust1.83%
3Fidus Re Ltd1.26%
4OneMain Direct Auto Receivables Trust1.04%
5Perrigo Finance Unlimite0.95%
6Ncl Corporation Ltd0.93%
7Uniti Group/csl Capital0.88%
8Hilcorp Energy I/hilcorp0.82%
9Ellington Financial Mortgage Trust0.81%
10Ellington Financial Mortgage Trust0.79%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 11.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to MDVAX

More funds like MDVAX →

MDVAX FAQ

What is the expense ratio of MDVAX?
MDVAX's expense ratio is 1.09%, which works out to about $109 a year for every $10,000 invested. The prospectus estimates total costs of $1,829 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is MDVAX a good investment?
It depends on your goals, but the data points to: broadly diversified (359 holdings); expensive for its category (1.09%); 5-year return in the bottom quarter of its category; front-end sales load up to 4.25%; 12b-1 marketing fee of 0.25% a year; high turnover (265% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does MDVAX hold?
MDVAX's largest holdings are State Street Global Advisors (2.4%), New Residential Mortgage Loan Trust (1.8%), Fidus Re Ltd (1.3%), OneMain Direct Auto Receivables Trust (1.0%), Perrigo Finance Unlimite (0.9%). It holds 359 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is MDVAX's 5-year return?
MDVAX returned −0.8% a year over the five years ending Dec 31, 2025, and +2.0% a year over ten years. Past performance does not guarantee future results.
Does MDVAX have a sales load?
Yes. MDVAX has a maximum front-end sales charge of 4.25%. It may charge a deferred sales charge of up to 1% if sold early.
Who manages MDVAX?
MDVAX is offered by T. Rowe Price through Massmutual Premier Funds.